Payment overview · 2025
General Payments
$1,014.73
36 reported records · 19 companies
Healthcare provider profile · identity verified
Mohammad Alsharabati, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neuromuscular Medicine · PALOS HEIGHTS, IL · NPI 1174748180
Verified facts
What the public records show
CMS Open Payments records show Mohammad Alsharabati, MD received $1,014.73 in general payments during 2025 across 36 reported records.
Janssen Biotech, Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Firdapse, Qulipta, Vyvgart, Vyvgart Hytrulo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Qulipta by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vyvgart by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART HYTRULO as an associated drug or biological on 16156 records involving 4992 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vyvgart Hytrulo by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Soliris by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FIRDAPSE as an associated drug or biological on 1474 records involving 920 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Firdapse by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $198.70 | 19.6% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $130.72 | 12.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $94.88 | 9.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.37 | 7.8% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $71.83 | 7.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $67.07 | 6.6% | 3 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $55.59 | 5.5% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $45.50 | 4.5% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $41.42 | 4.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.92 | 3.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $33.08 | 3.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.69 | 2.7% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $25.57 | 2.5% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.47 | 2.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.23 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.63 | 1.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 1.8% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.43 | 1.5% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.73 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $897.83 | 34 |
| Education | $116.90 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $130.72 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $94.88 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $79.37 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $71.83 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $67.07 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $35.92 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $35.58 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $27.69 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FIRDAPSE firdapse |
2025 | Firdapse | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART vyvgart |
2025 | Vyvgart | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART HYTRULO vyvgart hytrulo |
2025 | Vyvgart Hytrulo | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART HYTRULO open payments reported associated product |
CMS Open Payments — General Payments 16156 supporting records · 4992 recipient NPIs · example record 1240416058 |
Vyvgart Hytrulo · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FIRDAPSE open payments reported associated product |
CMS Open Payments — General Payments 1474 supporting records · 920 recipient NPIs · example record 1253216494 |
Firdapse · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 464 | 108 |
| Amitriptyline Hcl | Amitriptyline Hcl | 230 | 59 |
| Prednisone | Prednisone | 219 | 49 |
| Donepezil Hcl | Donepezil Hcl | 211 | 56 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 197 | 43 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 197 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 184 | 52 |
| Pregabalin | Pregabalin | 176 | 32 |
| Sodium Chloride | 0.9 % Sodium Chloride | 173 | 19 |
| Memantine Hcl | Memantine Hcl | 166 | 38 |
| Topiramate | Topiramate | 149 | 29 |
| Levetiracetam | Levetiracetam | 121 | 22 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 121 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 120 | suppressed |
| Azathioprine | Azathioprine | 111 | 20 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 106 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 73 | 17 |
| Emgality Pen | Galcanezumab-Gnlm | 72 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 72 | 15 |
| Lamotrigine | Lamotrigine | 70 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 19 |
| Baclofen | Baclofen | 65 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 63 | 16 |
| Aimovig Autoinjector | Erenumab-Aooe | 56 | suppressed |
| Carbamazepine Er | Carbamazepine | 54 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 53 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 52 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 48 | 11 |
| Meloxicam | Meloxicam | 45 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 41 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 34 | 12 |
| Topiramate Er | Topiramate | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 30 |
| Nurtec Odt | Rimegepant Sulfate | 30 | suppressed |
| Qulipta | Atogepant | 30 | suppressed |
| Riluzole | Riluzole | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 28 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Firdapse | Amifampridine Phosphate | 24 | suppressed |
| Acetazolamide | Acetazolamide | 23 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 22 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Vyvgart Hytrulo | Efgartigimod-Hyaluronidas-Qvfc | 20 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 18 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Solu-Cortef | Hydrocortisone Sodium Succ/Pf | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Soliris | Eculizumab | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,014.73 · 36 records | Janssen Biotech, Inc. | ACTHAR, AUSTEDO XR, EPIDIOLEX, FIRDAPSE, FYCOMPA, KESIMPTA, Motpoly XR, Nayzilam, Ocrevus Zunovo, PONVORY, QULIPTA, Radicava, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYVGART, VYVGART HYTRULO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Firdapse play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error